Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...
Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...